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1. Introduction 
Ion channels are transmembrane proteins with great importance for the human physiology 
and become highly attractive molecular drug targets. Ever since the development of patch 
clamp technique in the late 1970s, it remains the gold standard approach for functional 
analysis, providing both real time and mechanistic information. Currently, that nearly 400 
potential ion channels are found, indicating large-scale ion channel screening of wanted and 
unwanted drug effects is required (Venter et al., 2001). Unfortunately, it is limited by the 
lack of adequate screening approach, because available methods put a tradeoff between 
high-throughput and high-information content. The advent of automated patch clamp 
platforms revolutionize ion channel screening and enable investigations from a more 
functional perspective to a much more higher throughput. Compared with conventional 
patch clamp technique, the current status of automated patch clamp platforms also has 
some limitations. This chapter will provide the basic concepts of drug screening and drug 
safety evaluation by patch clamp technique and it moving from conventional to automated 
trend for high-throughput screening of ion channels.    
2. Ion channels as drug targets  
Ion channels are membrane proteins which form pores allowing ions to pass through 
impermeable cell membranes mediating and regulating crucial electrical functions 
throughout the body. Some channels are sensitive to membrane potential alteration and 
such channels are termed voltage-gated channels. Others have ligand binding sites to which 
a ligand can bind and change membrane permeability. They are so-called ligand-gated 
channels. It is estimated that there are more than 400 ion channel genes have been identified 
in the human genome, including about 170 potassium channels, 38 calcium channels, 29 
sodium channels, 58 chloride channels, and 15 glutamate receptors. The remaining are genes 
encoding other channels such as inositol triphosphate (IP3) receptors, transient receptor 
potential (TRP) channels and others (Venter et al., 2001; Fermini, 2008). 
In a range of disorders including pain, epilepsy, depression, stroke, bipolar disorder, COPD, 
arrhythmia, hypertension, autoimmune disorders and diabetes, over 55 different inherited 
ion channel diseases, known as ‘channelopathies’ have now been identified, suggesting ion 
channels are important therapeutic targets (Table 1) (Ashcroft, 2006). Recently, the 
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recognized importance of these proteins in physiological and pathological conditions has 
led to an extremely active search for ion channel targets in the worldwide drug discovery 
market. Approximately 13.4% of known drugs have their primary therapeutic action at ion 
channels, making them the second largest target class after G-protein coupled receptors 
(GPCRs) (Overington et al., 2006). These include the nicotinic, GABAA (Ǆ-aminobutyric acid 
A) and NMDA (N-methyl-d-aspartate) ligand-gated channels, the voltage-gated Na+, K+ and 
Ca2+ channels, and the ryanodine, inositol 1,4,5-trisphosphate (IP3) and transient receptor 
potential Ca2+ channel families (Imming et al., 2006). Worldwide sales of ion channel drugs 
are estimated to be in excess of $12 billion. For instance, ion channel modulators generated  
 
Drug Commercial 
Name 
Target 
channel 
Disease Indication
Amlodipine Norvasc L-Cav Angina, hypertension, arrhythmia (Hogg et 
al., 2006)
Felodipine Plendil L-Cav Hypertension (Hogg et al., 2006) 
Nifedipine Adalat L-Cav Angina, hypertension (Hogg et al., 2006) 
Verapamil Calan/
Verelan
L-Cav Angina, hypertension, arrhythmia (Hogg et 
al., 2006)
Diltiazem Cardizem/
Tiazac 
L-Cav Angina, hypertension, arrhythmia (Hogg et 
al., 2006) 
Nimodipine Nimotop L-Cav Angina, hypertension, arrhythmia (Hogg et 
al., 2006) 
Nifedipine Procardia L-Cav Angina, hypertension, arrhythmia  
(Hogg et al., 2006)
Carbamazepine Tegretol Nav Epilepsy (Chouinard, 2006)
Topiramate Topamax Nav Epilepsy (Chouinard, 2006)
Lamotrigine Lamictal Nav Epilepsy (Chouinard, 2006)
Flecainide Tambocor Nav1.5 Arrhythmia (Hogg et al., 2006) 
Lidocaine Lidocaine Nav Local anesthesia (Hogg et al., 2006) 
Gabapentin Neurontin Cavǂ2ǅ Pain (Hamer et al., 2002; Mathew et al., 
2001) 
Glimepiride Amaryl KATP Type-II diabetes (Proks & Lippiat, 2006) 
Glibenclimide Glimepiride KATP Diabetes (Proks & Lippiat, 2006) 
Nateglimide Starlix KATP Type-II diabetes (Proks & Lippiat, 2006) 
Zaleplon Sonata GABAA Insomnia (Kozlowski, 1999)
Benzodiazepine Diazepam GABA Depression (Kozlowski, 1999)
Ziconotide Prialt Cav2.2 Severe chronic pain (Hogg et al., 2006) 
Lubiprostone Amitiza CLC-2 Chronic idiopathic constipation  
(Kozlowski, 1999) 
Pregabalin Lyrica GABA Neuropathic pain (Kozlowski, 1999) 
Sotalol Betapace hERG Arrhythmia (Hogg et al., 2006) 
Amiodarone Cordorone hERG Arrhythmia (Hogg et al., 2006) 
Phenytion Dilantin Nav Epilepsy (Chouinard, 2006)
Flupirtine Flupirtine KCNQ2/3 Epilepsy (Chouinard, 2006)
Table 1. Current Ion Channel Drugs 
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over $1.2 billion sales in 2002. Amlodipine besylate, an antihypertensive of Pfizer inc., 
generated around $4 billion in revenue in 2003. Ambien and Xanax, chloride channel 
modulators, generated nearly $2 billion together in annual sales (Li et al., 2005). 
The current ion channel drugs are concluded in table 1, the table indicates that the 
pharmaceutical industry has successfully developed considerable drugs which targeted at 
selected calcium, potassium, sodium and chloride channels. Given the number of ion 
channel genes identified in the human genome project, it appears that there remains a 
significant pool of unexploited channels for tractable pharmacological target. 
3. The impact of hERG for drug toxicity evaluation 
In addition to being drug targets, as transmembrane proteins, ion channels are easily 
accessible for small molecules treatment and, in some cases, are also the direct cause of  
 
Name 
 
Indicator Potency Tissue Cell 
(Channel) (IC50, μM) (Species-Type) (Type) 
Astemizole (Salata et al., 1995)
 
Ikr
hERG 
0.0015
0.069 
GP-VM
 
XO 
Terfenadine Astemizole (Salata et al., 
1995) 
 
Ikr
hERG 
hERG 
0.05
0.431 
0.35 
Ibid.
 
 
Ibid. 
Ibid. 
MK-499 (Spector et al., 1996) hERG
WT-hERG
0.123
0.034
 
Ibid. 
Ibid. 
BRL-37872 (Thomas et al., 2001) hERG
hERG
0.241
0.0198
 
Ibid. 
HEK293 
Clofilium (Suessbrich et al., 1997b) hERG 0.25 XO 
LY97241 (Suessbrich et al., 1997b) hERG 0.019 Ibid. 
Haloperidol (Suessbrich et al., 1997a) hERG 0.024 Ibid. 
E4031 (Sanguinetti & Jurkiewicz, 
1990)
Ikr 0.497 GP-VM  
Quinidine (Woosley, 1996) Ikr 0.2 F-CM  
Desmethylastemizole (Vorperian et 
al., 1996; Zhou et al., 1999) 
Ikr
hERG 
0.02
0.001 
Rab-VM
 
HEK293 
Cisapride (Walker et al., 1999) hERG 0.0236 CHO 
Pimozide (Kang et al., 2000) hERG 0.018 Ibid. 
Bepridil (Chouabe et al., 1998) hERG 0.55 COS 
Droperidol (Drolet et al., 1999)
 
Ikr
hERG 
0.0276
0.032 
GP-VM
 
HEK293 
Sertindole (Rampe et al., 1998) hERG 0.014 L-cells 
Tedisamil (Zolotoy et al., 2003) TdP * 3  
Dofetilide (Yang et al., 1995) Ikr 0.012 AT-1 
Ibutilide (Yang et al., 1995) Ikr 0.02 AT-1 
Verapamil (Chouabe et al., 2000; 
Waldegger et al., 1999; Zhang et al., 
1999) 
hERG
hERG 
hERG 
0.14
0.83 
3.8 
 
HEK293 
 
XO 
Table 2. Potency of Strong HERG and Ikr Blockers 
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unwanted side-effects. In particular, the discovery of hERG channel and its underling role in 
prolongation of QT interval brings considerable attention on the drug safety liability issue 
and leads to the withdrawal or restricted use of several hERG-related drugs since 1997, 
including antihistamine Seldane, gastric prokinetic drug cisapride, antipsychotic sertindole, 
and even the antibiotic grepafloxacin (De Bruin et al., 2005; Vitola et al., 1998). 
Physiologically, hERG channel is closely related to the phase 3 repolarization in the action 
potential of human ventricular myocytes. The blockade of hERG leads to malfunction in 
cardiac excitability, clinically defines as either cardiac arrhythmia (torsade de pointes) or long 
QT syndrome, a cardiac repolarization disorder. In accordance with the requirement of FDA 
and the European Medicines Agency, before clinical trials, drug testing of known ion channels, 
especially hERG, are needed in order to rule out possible side effects (Morganroth, 2004). 
Compounds that have been validated with strong potency of hERG block are concluded in 
Table 2  
4. Conventional patch clamp technique 
Sakmann and Neher’s patch clamp electrophysiology technique is a highly accurate and 
sensitive recording method, which revolutionized ion channel research and remains the gold 
standard approach for functional analysis (Neher & Sakmann, 1992). Patch clamp technique 
can be operated in either voltage clamp or current clamp mode. Voltage clamp allows an 
experimenter to ‘clamp’ the cell potential at a chosen value. This makes it possible to measure 
voltage specific activity of ionic channels. The voltage-gated channels are primarily studied in 
this mode. Current clamp records the membrane potential changes in response to it. This 
technique is used to study how a cell responds when electrical current enters a cell. This type 
of recording are performed to study action potential firing by the neuron. 
Currently, there are a number of different patch clamp configurations and systems exist. The 
‘whole-cell’ configuration is the most common method for majority cultured cells and tissue 
preparations. Conventionally, the technique uses a glass microelectrode, sometimes called 
‘patch pipette’, containing an electrolyte resembling the fluid normally found within the cell 
(tip resistance 1-5 MΩ), which is positioned on the cell membrane with the aid of a 
microscope and micromanipulators, followed by gentle suction through the pipette to start 
seal formation. Once a high resistance (>1GΩ) seal between the rim of recording pipette and 
cell membrane is formed, further suction is applied to rupture the ‘clamped’ patch, allowing 
electrical access to the whole cell. The electrolyte freely dialyses from pipette to cell interior 
within minutes and the ionic gradients achieves equilibrium between the microelectrode 
and the cell. Patch clamp amplifier with low noise such as EPC form HEKA Electronik and 
Axopatch from Axon Instruments is utilized to monitor membrane potential with reference 
to a bath ground electrode, inject current to clamp the membrane potential to any voltage 
that we desire and detect current flow. Patch clamp technique can be operated in voltage 
and current clamp mode, which is, voltage steps or ramps, or current steps are applied to 
activate channels. Whole cell configuration monitors response of all ion channels within a 
cell membrane, currents as small as 10 pA, representing signals from just a few hundred 
open channels, can be recorded with sub-millisecond temporal resolution (Penner, 1995). 
Perforated patch clamp technique is a variant of whole cell recording method. It differs in 
which electrical access to the cell interior is obtained via membrane permeabilizing reagents, 
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typically nystatin or amphotericin, or with more potent gramicidin and saponin ǃ–Escin. 
After these antibiotics added to the internal recording solution, it takes 10-30 minutes to 
perforate cell. Compared with whole cell approach, it has some advantages, including 
produces minimal disruption to the intracellular milieu, offers reduced dialysis and 
generally allows for highly stable recordings, but the access resistance is higher. The main 
disadvantages are decreased current resolution and increased noise (Penner, 1995). 
Cell-attached, inside-out and outside-out patch clamp are called single channel recording 
technique. They sample channels from a small area (<10μm2) of the membrane rather than 
from the entire cell and study the behavior of ion channels on the section of membrane 
attached to the pipette. The cell-attached configuration is obtained by simply lowering the 
pipette onto the cell surface and measures currents arising from the channels which located 
within the diameter of the tip of recording pipette. A major disadvantage of this 
configuration is the entirely non-invasive of plasmalemma, making the application of 
pharmacological modulators to either side of the membrane becomes difficult, for this 
reason, it is largely restricted to biophysical analysis. By gently withdrawing the electrode 
from the cell after obtaining gigaohm seal, excising the patch inside the pipette tip, it is 
possible to form the inside-out recording configuration. With the internal aspect of the cell 
membrane now is exposed to the bath solution, compound acts on the inner facing channel 
can be readily achieved. This configuration is useful for studying the effects of alternative 
intracellular environment on single ion channel function. Outside-out patches are generated 
by first performing the whole cell recording and then slowly withdrawn the pipette from 
the cell membrane, a bleb of membrane separates from cell, creating a patch where the 
external aspect of cell membrane facing the bath solution. This is particularly attractive 
when studying the effects on single ion channel function of compounds applied to the 
extracellular solution (Fig 1) (Penner, 1995). 
Typically, a conventional patch clamp setup comprises of components as follow (Fig 2) 
(Kornreich, 2007):  
Micropipette puller: used to pull electrode from borosilicate glass capillary tubes. This 
process usually requires several pulls and may be either horizontal or vertical depending on 
protocol with user preference. Once pipettes have been pulled, they can be further fire-
polished by Pipette Beveler. 
Air suspension table: uses pressurized cylinders to ‘float’ the table so as to dampen the 
microscopic movements and vibrations that may interrupt the recording, and adds to 
achieve high resistance pipette membrane seals. 
Faraday cage: shields the sensitive patch clamp preamplifier from stray electromagnetic 
fields that may introduce noise into electrophysiological recordings. The microscope and 
headstage are also most commonly placed inside the Faraday cage. Ideally composed of a 
copper mesh, the Faraday cage is most effective when connected to a ground source.  
Inverted microscope: used to visualize the acutely dissociated cells or cultured cell lines 
being studied. This is important in order to obtain both good visualization of the cells and 
unhinder the flexible access of pipettes from the top. 
Micromanipulator: used to manipulate the electrode (mounted on the headstage) to contact 
the acutely dissociated cells or cultured cell lines being studied. Micromanipulators are 
commercially available in mechanical, hydraulic, motorized and piezoelectric drives. 
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Fig. 1. Formation of different types of patch (Kornreich, 2007)  
Amplifier: used to record current or voltage being measured and/or to control membrane 
voltage (voltage clamp) or current (current clamp) depending on experimental protocol. 
Additional functions also include filtering of input signal, capacitance compensation, and 
square wave generation etc. Using suitable software, the patch clamp recordings can be 
analyzed on a personal computer. For example, Pclamp (Axon), Pulse (Heka) and Jhon 
Dampaster’s WCP (UK) are some of the widely used software. 
Digital-analog converter: converts the analog signal recorded by the electrode to digital data, 
transforms digital output of computer to analog signal at headstage for control of membrane 
voltage/current, delivers stimulus protocols generated by computer to clamp ion channels. 
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Fig. 2. A conventional patch clamp setup comprising of 1) Faraday cage; 2) Solution 
perfusion system (EVH-9); 3) Inverted microscope; 4) CCD camera; 5) Motorized 
micromanipulator controller; 6) Air suspension table; 7) Temperature controller; 8) Digidata; 
9) Amplifier (Axopatch 200B); 10) Computer display; 11) Micromanipulator; 12) Rapid 
solution changer command box (RSC-200); 13) Computer monitor; 14) Micropipette puller; 
15) Micropipette Beveler. 
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Bath chamber: a small chamber with volume of 500 μl-1 ml used to mount on microscope, 
during experiments, the cells can be placed in this chamber. A thin glass slide is used to 
stick the bottom of chamber. 
Headstage: it is usually mounted on a micromanipulator, which connects the recording 
pipette and ground wire and contacts to the amplifier for data acquisition, control of 
membrane voltage/current, and stimulation release.  
Computer: uses suitable software packages to acquire and analyze data. These packages are 
used to control membrane voltage/current, to process the input/output signals from the 
amplifier (filtering, capacitance compensation, etc.), to perform stimulus protocols, and to 
analyze acquired data. 
5. Automated patch clamp technique 
As the state-of-the-art technology for studying ion channels, the patch clamp technique is 
limited only in the later stages of drug discovery and development, including hits-to-leads, 
safety testing and basic research, owing to the ultra-low-throughput and time-consuming 
process. Because of FDA’s new recommendations, at the preclinical stage, every drug 
candidate needs to be evaluated for their potential of hERG channel blockade. Therefore, a 
high-throughput drug screening approach is required as to accelerate the primary screening 
of ion channel modulators at the preliminary phase. Using a conventional patch clamp a 
sophisticated operator can study typically less than 10 cells per day, which is inefficient for 
large-scale screening for LQTS. Thus, there is a compelling need of high-throughput 
predictors of ion channel modulation to be developed. 
Automated patch clamp setup suitable to high-throughput screening has been marketed. 
The complicated process of seal formation and current recording has been partially or 
completely automated. This method utilizes planar chips with small holes, seal forming 
substrates can either be glass, silicon nitride or plastic. The cells approach to the chips based 
on computerized feedback controlled application of suction. According to the 
preprogrammed protocols, the automated patch clamp robots accurately execute operations, 
in turns of filling the chip with electrolyte solutions, adding cell suspensions, sealing cells 
onto the holes, breaking through to the whole-cell configuration and performing different 
voltage-protocols in the absence and presence of drugs while simultaneously recording the 
ionic currents. The benefit of automated technique is obvious, for instance, the manual 
handling has been removed from the whole process, machine operation is very 
straightforward, making it suitable to the nonelectrophysiologists and increasing data 
reproducibility. Besides, the technology is scalable to array formats, thus parallel recordings 
of many individual cells can be achieved. 
6. Limitations of automated patch clamping 
Although there are various advantages over the conventional technique, automated 
technique itself has some limitations. Firstly, it is suitable mainly for stable and highly 
expressing cell lines. Transiently transfected cell lines are unsuitable for screening. Because 
cells are captured randomly from cell suspension, which means that the ion channel 
expression must be homogenous among cells and most cells must be healthy. Primary 
cultured cells such as cardiac myocytes and neurons have different cell shapes, and do not 
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fit the criteria of the platform’s random loading system. In addition, the cultured primary 
cells often contain different cell types and that the suspensions are not ‘clean’ enough. 
However, there are some publications reported that the Ionworks and Patchliner have been 
used for primary cells (Estes et al., 2008). Other issues include some systems can not be used 
to study of ligand-gated ion channels, temperature control is unavailable, and when 
screening tens of thousands of compounds, the cost of the tips and chips is considerable 
high. Currently, most automated patch clamp systems are really limited in their applications 
and are not particularly useful for academic researches. The main practical application of 
automated patch clamp is secondary drug screening and safety profiling of hERG ion 
channel block.  
7. Available automated patch clamp systems  
There are several automated platforms commercially available, the first one appear into 
market was Ionworks HT and later Ionworks Quattro (Molecular Devices Corporation), 
succeeded by the Patch Xpress (Molecular Devices Corporation.) and Nanion’s Port-a-Patch. 
Other patch providers include Sophion’s QPatch-16 and -48, Flyion’s Flyscreen, Nanion’s 
Patchliner platform, Cytocentrics’s Cytopatch and Cellectricon’s Dynaflow Proll, providing 
16 to even 384 parallel recordings on a chip. Some of which including the PatchXpress, Port-
a-Patch, Patchliner, Flyscreen and the QPatch are the true giga-seal patch clamp recording 
platforms (Table 3).  
The above systems differ in some aspects, for instance, they adopt different solutions 
according to different materials used for the wells such as glass, silica or polymer, the 
number of wells on a chip can be various, commonly from 8 to 384, some systems utilize the 
technology of laminar solution flow in order to exchange different microfluids containing 
targeted compounds. The quality of the laminar flow is important because when evaluating 
the effects of different candidates or different concentrations of a candidate on ion channels, 
the fluids have to be completely exchanged without mixing (Neubert, 2004). Currently, there 
are two kinds of approaches with cells loading, one is the Flyscreen’s ‘Flip-the-tip’ technology, 
in this technique the cells are loaded in the specially designed pipette named ‘Flip-tips’ or 
‘Chip-tips’, and the cells are allowed to reach the tip. In contrast to the conventional method, 
external solution is filled in the pipette. The other is ‘Planar array’, which refers to the use of 
multi-well configurations in either a plate-based or a chip-based format to record multiple cells 
in parallel. In this technique, cells are loaded abruptly in the well and applying suction below 
the hole of the plates. Schematic representations of system assemblies (including bath, 
perfusion, cell trapping, and electrodes) are provided for each in Fig. 3. 
8. Ionworks 
Flyscreen: patch clamp robot Flyscreen 8500 from Flyion is a fully automated patch clamp 
system which is now commercially available in academic researches since 2003 (Lepple-
Wienhues et al., 2003). It uses flip-the-tip technology with glass capillaries rather than the 
planar-array based approach, in this system, cells are patch clamped on the inside rim of the 
pipette tip, different from conventional patch clamp. The so-called ‘flip-tips’ or ‘chip-tips’ 
are used to perform recordings. When cells travel to the pipette tips by gravity, only slight 
suction can lead to the formation of a gigaseal. The Flyscreen is also available with 
temperature control and allows recording at physiological temperature. This instrument is 
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designed to be scalable of asynchronously handling 1-6 recording positions and claims to 
have a throughput of 100-500 data points per day. 
IonWorks HT and IonWorks Quattro: the IonWorks HT system from Molecular Devices was 
the first marketed automated screening system with planar array-based approach in 2003 
(Schroeder et al., 2003). It uses a planar, multi-well plate named PatchPlate™ to replace the 
patch pipette (Fig. 3a). According to Molecular devices’ reports, this disposable ‘electrode’ 
contains 384 wells, however, the recording head has only 48 amplifiers, therefore the 
IonWorks HT is capable of sampling cells sequentially, imposing discontinuity in the 
recording of currents. In 2006, the upgraded IonWorks Quattro system was launched (Finkel 
et al., 2006). This technology belongs to the population patch clamp, differs in the IonWorks 
HT system’s recording mode of one cell in one hole in each well, it has 64 cells in 64 holes (in 
an 8×8 array) for each well (Fig. 3b), hence measured ion current from each well would be 
averaged and eliminates the cell-to-cell differences during recording.  
A major drawback of either the HT version or the Quattro version is that they do not 
support giga-seal recordings, the seal resistance is on the order of 100MΩ. This low seal 
resistance induces low data quality, owing to lower signal-to-noise ratio. Furthermore, an 
antibiotic amphotericin B, rather than suction is used to permeabilize the cell membrane and 
results in a drastically higher access resistance compared to conventional patch clamping, 
which in turn leads to poor voltage control over the membrane, possibly altering current 
amplitude and creates errors in quantification the pharmacology of the ion channels and 
drugs under investigation. Besides, another drawback of this system is the discontinuous 
recording during compound administration, which makes it not an ideal platform which 
suited to recording fast transient currents or ligand-gated currents. However, the Ionworks 
reports that more than 95% success rate has proved to be obtained, and it measures about 
3000 data points per day, this throughput has known to be the highest and is unmatched by 
other currently marketed devices, hence making it suitable for primary screening, secondary 
screening and safety assessment.  
PatchXpress 7000A: the second developed planar-array based automated screening system 
was the PatchXpress from Molecular Devices, it was also the first automated device on the 
market supporting true giga-seal recording and can analyze both ligand-gated and voltage-
gated ion channels (Tao et al., 2004; Xu et al., 2003). Their in-house developed software has 
versatile programming features, which is useful in testing operation and data analysis, and 
allows for continuous recordings during multiple drug concentrations’ applications. This 
system uses Aviva Bioscience’s SealChips, a 16-well disposable that has been reported to 
patch more than 12 cells (one cell per well) simultaneously for more than 15 min (Fig. 3d). 
Because of its high giga-seal rates, the longevity of seals comparable to glass pipettes, its 
versatile software allows the user to program any experimental protocol and its versatility 
of suitable to all kinds of ion channels. The PatchXpress has been considered as the golden 
standard in the field for automated electrophysiology. However, its throughput is stated to 
be 250-300 data points per day, compared with the throughputs of other available systems, 
is too low for true high-throughput screening. 
Port-a-Patch and Patchliner: in 2003, Nanion introduced its first automated patch clamp 
system, the Port-a-Patch which is the third system marketed to automate voltage clamping. 
It is currently the world’s smallest patch clamp setup with low maintenance setup. This 
system uses borosilicate glass chips which named NPC-chips as recording substrates. Port-
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a-Patch is a one-cell-at-a-time system. In 2006, Nanion attempted a higher-throughput 
device, the Patchliner, which supports true giga-seal recordings from up to eight cells 
simultaneously. It also expands the microfluidic exchange capability of both the internal and 
the external solutions (Farre et al., 2007). Three NPC-16 chips can be mounted on the chip 
loading area which means that up to 48 experiments can be preprogrammed and executed, 
where patch clamp measurements are possible in the whole-cell, cell-attached and 
perforated-patch recording configurations, and temperature controller in these two 
platforms supports experiments at physiological temperatures (Fig 3e). The Port-a-Patch has 
an approximate date throughput of 50 data points per day, whereas the Patchliner is capable 
of 500 data points per day. The throughput for this device was insufficient to compete 
successfully on the market and has remained unpopular. Recently, Nanion developed the 
SyncroPatch 96, which uses 96-well chips and has 96 simultaneous recording heads, with a 
throughput comparable to that of the IonWorks Quattro. 
CytoPatch: the Cytocentrics’s CytoPatch was the fourth system launched, this platform also 
uses planar-based array approach, but its designer has a slight difference from previous 
systems (Stett et al., 2003). It adopts CytopatchTM Chips and CytopatchTM Automat as 
electrode tip, which containing two opening, one for applying negative pressure to suction 
and to position the cells while simultaneously applying positive pressure to the “electrode 
tip” to keep it clean, the other for patch clamping and recording (Fig. 3f). These chips can be 
manufactured in large numbers at low cost and provide the formation of gigaohm seal. 
Although this device was released in 2003, there was no validation data available till now. 
QPatch: the Sophion’s QPatch was the fifth automated giga-seal system released (Fig. 3c) 
in 2004, which can be applied to both voltage- and ligand-gated channels (Mathes, 2006). 
This workstation can be manipulated and data can be analyzed with in-house developed 
software in computers. The first marketed system is QPatch 16 which uses QPlates as 
recording chips. This system provides 16 continuous recordings with 16 simultaneous 
headstages. To get a further higher throughput, Sophion recently launched the QPatch-
HT, increased the number of headstages to 48 providing parallel recordings of 48 cells at a 
time. The stated throughput of the 16-amplifier system is 250-1200 data points and a 
significant enhancement of 750-3500 data points per day for the HT-system. Because of the 
high-quality recordings and the increased throughput, QPatch now has received quite 
good market acceptance. 
Between 2007 and 2009, Fluxion Biosciences employed the so-called lateral patch clamp 
principle and introduced the IonFlux, a 16× precursor and the upcoming IonFlux HT (Fig. 
3g)( Pearson, 2009). IonFlux uses PDMS-based microfluidic chips, according to the company, 
producing 8,000-10,000 data per day with a 96× consumable. In collaborate with 
AstraZeneca and The Automation Partnership (TAP), Cellectricon employs their laminar-
flow solution control to develop a recently announced Dynaflow®HT (Fig. 3h) (Dabrowski, 
2009). The system uses 96-well microfluidic chips made from silicone which enable to rapid 
solution exchange. The system achieved over 7,500 data points per day at first, but with the 
introduction of a new chip in 2009, the Dynaflow HT system generates 18,000 data points 
per day. Consistent with the IonFlux HT workstaion and many other high-throughput 
planar devices, Dynaflow HT has been validated with multiple cell lines including both 
voltage- and ligand-gated ion channels. 
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Method Configuration Format Advantages Shortcomings 
QPatch (Sophion Bioscience)
Planar 
QPlate with 
embedded 
recording 
and ground 
contacts 
WC; gigaohm 
seals 
16 or 48 wells in 
parallel; 1 
cell/hole/well 
 Laminar solution 
flow 
 Ligand addition 
during recordings 
 Cumulative/multiple 
compound additions
 Continuous voltage 
clamp and current 
vs. time experiment 
flow 
 Validated for human 
ERG 
 Electrophysiological 
responses similar to 
those of conventional 
techniques 
 Drug EC50 
influenced by 
adherence to 
plate surfaces  
 No intracellular 
perfusion 
 No 
simultaneous 
visualization of 
channels 
PatchXpress (Molecular Devices)
Planar 
SealChip 
with 
electrodes 
separate 
from chip 
WC; gigaohm 
seals 
16 wells in 
parallel; 1 
cell/hole/well 
 Continuous voltage 
clamp vs. time plots 
 Cumulative/multiple 
compound additions
 Ligand addition 
during recording 
 Simultaneous 
visualization of all 16 
channels 
 Validated for human 
ERG 
 Electrophysiological 
responses similar 
to those of 
conventional 
techniques 
 Drug EC50 
influenced by 
adherence to 
plate surfaces  
 No intracellular 
perfusion 
IonWorks HT and Quattro (Molecular Devices)
Planar 384-
well 
PatchPlate 
Perforated 
WC; ~100 MΩ 
(HT) or 30–50 
384 wells; 48 
channels 
sequentially; 1 
 Highest-throughput 
unit 
 Allows for collection 
 Drug EC50 
influenced by 
adherence to 
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MΩ (Quattro) 
seals 
cell/hole/well 
(HT) or 64 
cells/holes/well 
(Quattro) 
of 384 data points: 
~60% success rate for 
IonWorks HT and 
>95% for IonWorks 
Quattro 
plate surfaces  
 No high-
resistance 
membrane seal 
 No 
simultaneous 
ligand addition 
and recording 
 No intracellular 
perfusion 
 No voltage 
clamp between 
reads 
Patchliner (Nanion Technologies)
Planar 
NPC-16 
chip 
WC; gigaohm 
seals 
2, 4, or 8 wells 
in parallel; 1 
cell/hole/well 
(Port-a-Patch) 
 Borosilicate chip 
surface 
 Primary cell use 
possible (single-well 
version) 
 Internal and external 
perfusion 
 Continuous voltage 
vs. time plots 
 Ligand addition 
during recordings 
 Cumulative/multiple 
compound additions
 System 
performance 
information 
limited 
SyncroPatch96 (Nanion Technologies)
Planar chip WC; gigaohm 
seals 
96-well plates; 
16 channels 
sequentially; 1 
cell/hole/well 
 Borosilicate chip 
surface 
 Ligand addition 
during recordings 
 Internal and external 
perfusion 
 Continuous voltage 
vs. time plots 
 Cumulative/multiple 
compound additions
 Requires a 
proprietary add-
in to solutions to 
achieve higher 
seal rate  
 Though meant 
for 96x, does not 
contain 96 
amplifiers  
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CytoPatch (Cytocentrics)
Planar, 
electrode 
tip shape 
surrounded 
by aperture 
in 
borosilicate 
glass 
surface 
WC 1 cell/hole/well  Constant laminar 
flow 
 Positive pressure on 
electrode is 
independent of 
suction in 
surrounding aperture 
(mimics manual 
patch clamp) 
 Not 
commercially 
available; used 
only for in-
house screening 
IonFlux HT (Fluxion Biosciences)
Microfluidic 
well plate 
WC; 
megaohm 
seals 
96- or 384-well; 
16 or 64 (HT) 
amplifier arrays;
20 cell ensemble 
recordings 
 Laminar solution 
flow 
 Ligand addition 
during recordings 
 Cumulative/multiple 
compound additions
 Continuous voltage 
vs. time plots 
 Tested with voltage- 
and ligand-gated 
channels 
 Separate cell and 
ligand wells 
 Drug EC50 
influenced by 
adherence to 
polymer plate 
surfaces?  
 No high-
resistance 
membrane seal 
Dynaflow HT (Cellectricon / The Automation Partnership / Astra Zeneca)
Microfluidic 
well plate 
WC; 
megaohm 
seals 
96 
channels/plate 
 Ligand addition 
during recordings 
 Cumulative/multiple 
compound additions
 Silica microfluidic 
chip minimizes 
compound adherence 
and consequent EC50 
shifting  
 Validated for human 
ERG and GABAA  
 No high-
resistance 
membrane seal 
Table 3. Automated planar-array based platforms (Carmelle et al., 2011; Dunlop et al., 2008).  
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Fig. 3. Chamber configurations for automated and planar patch clamp technologies. (a) 
PatchPlate used in IonWorks HT. (b) PatchPlate population chip used in IonWorks Quattro. 
(c) QPlate used in QPatch. (d)SealChip used in PatchXpress. (e) NPC-16 chip used in 
Patchliner NPC-16. (f) CytoPatch chip used in CytoPatch. (g) Microfluidic bath used in the 
IonFlux HT system. (h) Microfluidic bath used in the Dynaflow HT syste (Carmelle, 2011) 
9. Future directions for new drug discovery 
The development of new drugs targeted to ion channels is a fast-growing market. Along with 
the costs of automated screening drop over time and the modification of patch clamp devices 
gradually live up to expectations, the manufacturers of patch clamp equipment have already 
acquired considerable number of orders during the past few years from pharmaceutical 
companies and numerous screening service providers. Recently, patch clamp combined with 
fluorescent techniques are developed, this technology has achieved in a small number of 
channels, allowing to simultaneously recording of fluorescence and currents, hence providing 
correlation between changes in channel structure and alterations in channel function (Zheng, 
2006). These progresses open a new visual field in the upcoming era of ion channels studying 
as well as drug discovery. 
10. References 
Ashcroft, F.M. (2006). From molecule to malady. Nature 440, 440-447 
Carmelle, V., Remillard & Jason, X.J. Yuan. (2011) Conventional patch clamp techniques and 
high-throughput patch clamp recordings on a chip for measuring ion channel 
activity. Textbook of pulmonary vascular disease, part 2, 495-510, DOI: 10.1007/978-0-
387-87429-6_34 
www.intechopen.com
 Patch Clamp Technique 
 
326 
Chouabe, C., Drici, M.D., Romey, G. & Barhanin, J. (2000). Effects of calcium channel 
blockers on cloned cardiac K+ channels IKr and IKs. Therapie 55, 195-202 
Chouabe, C., Drici, M.D., Romey, G., Barhanin, J. & Lazdunski, M. (1998). HERG and 
KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets 
for calcium channel blockers. Mol Pharmacol 54, 695-703 
Chouinard, G. (2006). The search for new off-label indications for antidepressant, 
antianxiety, antipsychotic and anticonvulsant drugs. J Psychiatry Neurosci 31, 168-
176 
Dabrowski, M. (2009) Global ion channel initiative. Ion Channel Retreat June 29-July 1 See 
also the Cellectricon web site 
De Bruin, M.L., Pettersson, M., Meyboom, R.H., Hoes, A.W. & Leufkens, H.G. (2005). Anti-
HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur 
Heart J 26, 590-597 
Drolet, B., Zhang, S., Deschenes, D., Rail, J., Nadeau, S., Zhou, Z., January, C.T. & Turgeon, J. 
(1999). Droperidol lengthens cardiac repolarization due to block of the rapid 
component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 
10, 1597-1604 
Dunlop, J., Bowlby, M., Peri, R., Vasilyev, D. & Arias, R. (2008). High-throughput 
electrophysiology: an emerging paradigm for ion-channel screening and 
physiology. Nat Rev Drug Discov 7, 358-368 
Estes, D.J., Memarsadeghi, S., Lundy, S.K., Marti, F., Mikol, D.D., Fox, D.A. & Mayer, M. 
(2008). High-throughput profiling of ion channel activity in primary human 
lymphocytes. Anal Chem 80, 3728-3735 
Farre, C., Stoelzle, S., Haarmann, C., George, M., Bruggemann, A. & Fertig, N. (2007). 
Automated ion channel screening: patch clamping made easy. Expert Opin Ther 
Targets 11, 557-565 
Finkel, A., Wittel, A., Yang, N., Handran, S., Hughes, J. & Costantin, J. (2006). Population 
patch clamp improves data consistency and success rates in the measurement of 
ionic currents. J Biomol Screen 11, 488-496 
Hamer, A.M., Haxby, D.G., McFarland, B.H. & Ketchum, K. (2002). Gabapentin use in a 
managed medicaid population. J Manag Care Pharm 8, 266-271 
Hogg, D.S., Boden, P., Lawton, G. & Kozlowski, R. (2006) Ion channel drug targets-
unlocking the potential. Drug discov world, Vol.7, No.3, (August 2006), pp. 83-93, 
ISSN 1469-4344 
Imming, P., Sinning, C. & Meyer, A. (2006). Drugs, their targets and the nature and number 
of drug targets. Nat Rev Drug Discov 5, 821-834 
Kang, J., Wang, L., Cai, F. & Rampe, D. (2000). High affinity blockade of the HERG cardiac 
K(+) channel by the neuroleptic pimozide. Eur J Pharmacol 392, 137-140 
Kornreich, B.G. (2007). The patch clamp technique: principles and technical considerations. J 
Vet Cardiol 9, 25-37 
Kozlowski, R.Z. (1999) Chloride channels: Potential therapeutic targets, In: Chloride Channels, 
R.Z. Kozlowski, (Ed.), 177-186, ISIS Medical Media Ltd, Oxford, UK 
Lepple-Wienhues, A., Ferlinz, K., Seeger, A. & Schafer, A. (2003). Flip the tip: an automated, 
high quality, cost-effective patch clamp screen. Receptors Channels 9, 13-17 
Li, S., Gosling, M., Poll, C.T., Westwick, J. & Cox, B. (2005). Therapeutic scope of modulation 
of non-voltage-gated cation channels. Drug Discov Today 10, 129-137 
www.intechopen.com
 Drug Screening and Drug Safety Evaluation by Patch Clamp Technique 
 
327 
Mathes, C. (2006). QPatch: the past, present and future of automated patch clamp. Expert 
Opin Ther Targets 10, 319-327 
Mathew, N.T., Rapoport, A., Saper, J., Magnus, L., Klapper, J., Ramadan, N., Stacey, B. & 
Tepper, S. (2001). Efficacy of gabapentin in migraine prophylaxis. Headache 41, 
119-128. 
Morganroth, J. (2004). A definitive or thorough phase 1 QT ECG trial as a requirement for 
drug safety assessment. J Electrocardiol 37, 25-29 
Neher, E. & Sakmann, B. (1992). The patch clamp technique. Sci Am 266, 44-51 
Neubert, H.J. (2004). Patch clamping moves to chips. Anal Chem 76, 327A-330A 
Overington, J.P., Al-Lazikani, B. & Hopkins, A.L. (2006). How many drug targets are there? 
Nat Rev Drug Discov 5, 993-996 
Pearson, S. (2009) Investigating and focusing on ion channels as drug targets. Genetic Eng 
Biotech News Vol.29, No.11 
Penner, R. (1995) A practical guide to patch clamping, in: Single-Channel Recording, B. 
Sakmann & E. Neher, eds., (2nd ed). Plenum Press, NY, pp.3-30 
Proks, P. & Lippiat, J.D. (2006). Membrane ion channels and diabetes. Curr Pharm Des 12, 
485-501 
Rampe, D., Murawsky, M.K., Grau, J. & Lewis, E.W. (1998). The antipsychotic agent 
sertindole is a high affinity antagonist of the human cardiac potassium channel 
HERG. J Pharmacol Exp Ther 286, 788-793 
Salata, J.J., Jurkiewicz, N.K., Wallace, A.A., Stupienski, R.F., 3rd, Guinosso, P.J., Jr. & Lynch, 
J.J., Jr. (1995). Cardiac electrophysiological actions of the histamine H1-receptor 
antagonists astemizole and terfenadine compared with chlorpheniramine and 
pyrilamine. Circ Res 76, 110-119 
Sanguinetti, M.C. & Jurkiewicz, N.K. (1990). Two components of cardiac delayed rectifier K+ 
current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen 
Physiol 96, 195-215 
Schroeder, K., Neagle, B., Trezise, D.J. & Worley, J. (2003). Ionworks HT: a new high-
throughput electrophysiology measurement platform. J Biomol Screen 8, 50-64 
Spector, P.S., Curran, M.E., Keating, M.T. & Sanguinetti, M.C. (1996). Class III 
antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. 
Open-channel block by methanesulfonanilides. Circ Res 78, 499-503 
Stett, A., Burkhardt, C., Weber, U., van Stiphout, P. & Knott, T. (2003). CYTOCENTERING: a 
novel technique enabling automated cell-by-cell patch clamping with the 
CYTOPATCH chip. Receptors Channels 9, 59-66 
Suessbrich, H., Schonherr, R., Heinemann, S.H., Attali, B., Lang, F. & Busch, A.E. (1997a). 
The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium 
channels expressed in Xenopus oocytes. Br J Pharmacol 120, 968-974 
Suessbrich, H., Schonherr, R., Heinemann, S.H., Lang, F. & Busch, A.E. (1997b). Specific 
block of cloned Herg channels by clofilium and its tertiary analog LY97241. FEBS 
Lett 414, 435-438 
Tao, H., Santa Ana, D., Guia, A., Huang, M., Ligutti, J., Walker, G., Sithiphong, K., Chan, F., 
Guoliang, T., Zozulya, Z., et al. (2004). Automated tight seal electrophysiology for 
assessing the potential hERG liability of pharmaceutical compounds. Assay Drug 
Dev Technol 2, 497-506 
www.intechopen.com
 Patch Clamp Technique 
 
328 
Thomas, D., Wendt-Nordahl, G., Rockl, K., Ficker, E., Brown, A.M. & Kiehn, J. (2001). High-
affinity blockade of human ether-a-go-go-related gene human cardiac potassium 
channels by the novel antiarrhythmic drug BRL-32872. J Pharmacol Exp Ther 297, 
753-761 
Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., 
Yandell, M., Evans, C.A., Holt, R.A., et al. (2001). The sequence of the human 
genome. Science 291, 1304-1351 
Vitola, J., Vukanovic, J. & Roden, D.M. (1998). Cisapride-induced torsades de pointes. J 
Cardiovasc Electrophysiol 9, 1109-1113 
Vorperian, V.R., Zhou, Z., Mohammad, S., Hoon, T.J., Studenik, C. & January, C.T. (1996). 
Torsade de pointes with an antihistamine metabolite: potassium channel blockade 
with desmethylastemizole. J Am Coll Cardiol 28, 1556-1561 
Waldegger, S., Niemeyer, G., Morike, K., Wagner, C.A., Suessbrich, H., Busch, A.E., Lang, F. 
& Eichelbaum, M. (1999). Effect of verapamil enantiomers and metabolites on 
cardiac K+ channels expressed in Xenopus oocytes. Cell Physiol Biochem 9, 81-89 
Walker, B.D., Singleton, C.B., Bursill, J.A., Wyse, K.R., Valenzuela, S.M., Qiu, M.R., Breit, 
S.N. & Campbell, T.J. (1999). Inhibition of the human ether-a-go-go-related gene 
(HERG) potassium channel by cisapride: affinity for open and inactivated states. Br 
J Pharmacol 128, 444-450 
Woosley, R.L. (1996). Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 36, 
233-252 
Xu, J., Guia, A., Rothwarf, D., Huang, M., Sithiphong, K., Ouang, J., Tao, G., Wang, X. & Wu, 
L. (2003). A benchmark study with sealchip planar patch-clamp technology. Assay 
Drug Dev Technol 1, 675-684 
Yang, T., Snyders, D.J. & Roden, D.M. (1995). Ibutilide, a methanesulfonanilide 
antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ 
current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent 
effects. Circulation 91, 1799-1806 
Zhang, S., Zhou, Z., Gong, Q., Makielski, J.C. & January, C.T. (1999). Mechanism of block 
and identification of the verapamil binding domain to HERG potassium channels. 
Circ Res 84, 989-998 
Zheng, J. (2006). Patch fluorometry: shedding new light on ion channels. Physiology 
(Bethesda) 21, 6-12 
Zhou, Z., Vorperian, V.R., Gong, Q., Zhang, S. & January, C.T. (1999). Block of HERG 
potassium channels by the antihistamine astemizole and its metabolites 
desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 10, 836-843 
Zolotoy, A.B., Plouvier, B.P., Beatch, G.B., Hayes, E.S., Wall, R.A. & Walker, M.J. (2003). 
Physicochemical determinants for drug induced blockade of HERG potassium 
channels: effect of charge and charge shielding. Curr Med Chem Cardiovasc 
Hematol Agents 1, 225-241 
www.intechopen.com
Patch Clamp Technique
Edited by Prof. Fatima Shad Kaneez
ISBN 978-953-51-0406-3
Hard cover, 356 pages
Publisher InTech
Published online 23, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is a stimulating and interesting addition to the collected works on Patch clamp technique. Patch
Clamping is an electrophysiological technique, which measures the electric current generated by a living cell,
due to the movement of ions through the protein channels present in the cell membrane. The technique was
developed by two German scientists, Erwin Neher and Bert Sakmann, who received the Nobel Prize in 1991 in
Physiology for this innovative work. Patch clamp technique is used for measuring drug effect against a series
of diseases and to find out the mechanism of diseases in animals and plants. It is also most useful in finding
out the structure function activities of compounds and drugs, and most leading pharmaceutical companies
used this technique for their drugs before bringing them for clinical trial. This book deals with the
understanding of endogenous mechanisms of cells and their receptors as well as advantages of using this
technique. It covers the basic principles and preparation types and also deals with the latest developments in
the traditional patch clamp technique. Some chapters in this book take the technique to a next level of
modulation and novel approach. This book will be of good value for students of physiology, neuroscience, cell
biology and biophysics.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Yan Long and Zhiyuan Li (2012). Drug Screening and Drug Safety Evaluation by Patch Clamp Technique,
Patch Clamp Technique, Prof. Fatima Shad Kaneez (Ed.), ISBN: 978-953-51-0406-3, InTech, Available from:
http://www.intechopen.com/books/patch-clamp-technique/drug-screening-and-drug-safety-evaluation-by-
patch-clamp-technique
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
